<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01378468</url>
  </required_header>
  <id_info>
    <org_study_id>The Berlin 'Cream&amp;Sugar' Study</org_study_id>
    <secondary_id>2009-010356-97</secondary_id>
    <nct_id>NCT01378468</nct_id>
  </id_info>
  <brief_title>Prognostic Impact of an Oral Triglyceride Tolerance Test in Patients After Acute Ischemic Stroke</brief_title>
  <official_title>The Berlin 'Cream&amp;Sugar' Study: the Prognostic Impact of an Oral Triglyceride Tolerance Test in Patients After Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-fasting triglyceride levels are thought to play a role in stroke. The investigators&#xD;
      hypothesise that the results of a standardised oral triglyceride tolerance test in the&#xD;
      subacute setting (3-7 days) after the first ischaemic stroke are associated with the risk of&#xD;
      recurrent stroke within 12 months after the index event.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since high postprandial triglycerides levels may be a risk factor for stroke, we use a&#xD;
      combined oral triglyceride and glucose tolerance test in patients who had a first ischemic&#xD;
      stroke. Follow-up after one year primarily assesses wether or not a recurrent stroke has&#xD;
      occured. The glucose tolerance test is meant to identify patients with metabolic syndrome&#xD;
      (and diabetes), since this condition is per se associated with increased levels of&#xD;
      triglycerides. Potentially, the post-challenge triglyceride levels only play a role in&#xD;
      patients without diabetes or metabolic syndrome. For further details see Ebinger et al. 'The&#xD;
      Berlin 'Cream&amp;Sugar' Study: the prognostic impact of an oral triglyceride tolerance test in&#xD;
      patients after acute ischaemic stroke', IJS; 2010,5, 47-51.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent Stroke</measure>
    <time_frame>outcome measure is assessed one year after first ischemic stroke.</time_frame>
    <description>The primary end-point of the study is a recurrent fatal or nonfatal stroke within the first 12 months after the event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MI</measure>
    <time_frame>one year after first ischemic stroke</time_frame>
    <description>Myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>one year after first ischemic stroke</time_frame>
    <description>cardiovascular death (death due to any cardiovascular or cerebrovascular event)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIA</measure>
    <time_frame>one year after first ischemic stroke</time_frame>
    <description>transient ischemic attack</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">573</enrollment>
  <condition>First Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Patients with first ischemic stroke</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oral triglyceride tolerance test (not a therapeutic &quot;intervention&quot; as such but a new diagnostic test)</intervention_name>
    <description>see Ebinger et al., IJS, 2010</description>
    <arm_group_label>Patients with first ischemic stroke</arm_group_label>
    <other_name>cream</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        the study population consists of adults with first ischemic stroke within the last three to&#xD;
        seven days (at time of testing).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  First ischemic stroke&#xD;
&#xD;
          -  Incidence within less than 7 days&#xD;
&#xD;
          -  Informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Aphasia (if hampering informed consent)&#xD;
&#xD;
          -  Swallowing disorder&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Renal or hepatic failure&#xD;
&#xD;
          -  Pancreatitis&#xD;
&#xD;
          -  Cholecystolithiasis&#xD;
&#xD;
          -  Malabsorption&#xD;
&#xD;
          -  Lactose intolerance&#xD;
&#xD;
          -  Psychosis&#xD;
&#xD;
          -  Drug and/or alcohol addiction&#xD;
&#xD;
          -  Expected life expectancyr12 months&#xD;
&#xD;
          -  Inability to sign informed consent&#xD;
&#xD;
          -  Acute coronary syndrome&#xD;
&#xD;
          -  Severe heart valve disorder&#xD;
&#xD;
          -  Heart failure (NYHA III-IV)&#xD;
&#xD;
          -  Severe infectious/rheumatic disease&#xD;
&#xD;
          -  Sever metabolic disease&#xD;
&#xD;
          -  No oral glucose tolerance test in case of known diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Ebinger</last_name>
    <role>Principal Investigator</role>
    <affiliation>CSB</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthias Endres</last_name>
    <role>Principal Investigator</role>
    <affiliation>CSB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Ebinger M, Heuschmann PU, Jungehuelsing GJ, Werner C, Laufs U, Endres M. The Berlin 'Cream&amp;Sugar' Study: the prognostic impact of an oral triglyceride tolerance test in patients after acute ischaemic stroke. Int J Stroke. 2010 Apr;5(2):126-30. doi: 10.1111/j.1747-4949.2010.00399.x.</citation>
    <PMID>20446947</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2011</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Martin Ebinger</investigator_full_name>
    <investigator_title>PD Dr. med. Dr. phil.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

